nodes	percent_of_prediction	percent_of_DWPC	metapath
Montelukast—CYP2A6—Methoxsalen—psoriasis	0.129	0.18	CbGbCtD
Montelukast—CYP2C8—Tazarotene—psoriasis	0.0985	0.138	CbGbCtD
Montelukast—CYP2A6—Prednisolone—psoriasis	0.0626	0.0876	CbGbCtD
Montelukast—CYP2C8—Cholecalciferol—psoriasis	0.0421	0.0588	CbGbCtD
Montelukast—CYP2A6—Dexamethasone—psoriasis	0.0369	0.0516	CbGbCtD
Montelukast—CYP2C8—Mycophenolate mofetil—psoriasis	0.0365	0.051	CbGbCtD
Montelukast—CYP3A4—Calcitriol—psoriasis	0.0331	0.0463	CbGbCtD
Montelukast—CYP2C9—Cholecalciferol—psoriasis	0.0293	0.041	CbGbCtD
Montelukast—CYP2C8—Hydrocortisone—psoriasis	0.0293	0.0409	CbGbCtD
Montelukast—CYP2C8—Cyclosporine—psoriasis	0.0276	0.0387	CbGbCtD
Montelukast—CYP3A4—Methoxsalen—psoriasis	0.0257	0.036	CbGbCtD
Montelukast—CYP2C9—Cyclosporine—psoriasis	0.0193	0.027	CbGbCtD
Montelukast—CYP2C8—Dexamethasone—psoriasis	0.0182	0.0255	CbGbCtD
Montelukast—CYP3A4—Cholecalciferol—psoriasis	0.0171	0.0239	CbGbCtD
Montelukast—CYP3A4—Mycophenolate mofetil—psoriasis	0.0148	0.0207	CbGbCtD
Montelukast—CYP3A4—Triamcinolone—psoriasis	0.0148	0.0207	CbGbCtD
Montelukast—CYP2C9—Dexamethasone—psoriasis	0.0127	0.0178	CbGbCtD
Montelukast—CYP3A4—Betamethasone—psoriasis	0.0127	0.0178	CbGbCtD
Montelukast—CYP3A4—Prednisolone—psoriasis	0.0125	0.0175	CbGbCtD
Montelukast—CYP3A4—Hydrocortisone—psoriasis	0.0119	0.0166	CbGbCtD
Montelukast—CYP3A4—Prednisone—psoriasis	0.0118	0.0165	CbGbCtD
Montelukast—CYP3A4—Cyclosporine—psoriasis	0.0112	0.0157	CbGbCtD
Montelukast—CYP3A4—Dexamethasone—psoriasis	0.00738	0.0103	CbGbCtD
Montelukast—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.00213	0.092	CbGpPWpGaD
Montelukast—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00146	0.0629	CbGpPWpGaD
Montelukast—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.00132	0.0571	CbGpPWpGaD
Montelukast—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00119	0.0512	CbGpPWpGaD
Montelukast—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000903	0.039	CbGpPWpGaD
Montelukast—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000735	0.0317	CbGpPWpGaD
Montelukast—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000549	0.0237	CbGpPWpGaD
Montelukast—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000542	0.0234	CbGpPWpGaD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00051	0.022	CbGpPWpGaD
Montelukast—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000485	0.0209	CbGpPWpGaD
Montelukast—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000471	0.0203	CbGpPWpGaD
Montelukast—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000445	0.0192	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—HCAR2—psoriasis	0.000388	0.0167	CbGpPWpGaD
Montelukast—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000375	0.0162	CbGpPWpGaD
Montelukast—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00037	0.016	CbGpPWpGaD
Montelukast—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000347	0.015	CbGpPWpGaD
Montelukast—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000344	0.0148	CbGpPWpGaD
Montelukast—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000305	0.0132	CbGpPWpGaD
Montelukast—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000304	0.0131	CbGpPWpGaD
Montelukast—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000301	0.013	CbGpPWpGaD
Montelukast—ALOX5—Selenium Micronutrient Network—CAT—psoriasis	0.000296	0.0128	CbGpPWpGaD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000265	0.0114	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.00025	0.0108	CbGpPWpGaD
Montelukast—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000247	0.0107	CbGpPWpGaD
Montelukast—CYSLTR1—Endothelins—JUN—psoriasis	0.00024	0.0103	CbGpPWpGaD
Montelukast—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000236	0.0102	CbGpPWpGaD
Montelukast—ALOX5—Selenium Micronutrient Network—CRP—psoriasis	0.000235	0.0101	CbGpPWpGaD
Montelukast—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000228	0.00983	CbGpPWpGaD
Montelukast—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000226	0.00975	CbGpPWpGaD
Montelukast—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000219	0.00947	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—HCAR2—psoriasis	0.000219	0.00946	CbGpPWpGaD
Montelukast—ALOX5—Selenium Micronutrient Network—ICAM1—psoriasis	0.000216	0.00932	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—CCL20—psoriasis	0.000202	0.0087	CbGpPWpGaD
Montelukast—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000201	0.00869	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—HCAR2—psoriasis	0.000199	0.00859	CbGpPWpGaD
Montelukast—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000199	0.00859	CbGpPWpGaD
Montelukast—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000199	0.00857	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—CP—psoriasis	0.000197	0.0085	CbGpPWpGaD
Montelukast—Paraesthesia—Cyclosporine—psoriasis	0.000179	0.000682	CcSEcCtD
Montelukast—Cough—Triamcinolone—psoriasis	0.000178	0.000679	CcSEcCtD
Montelukast—Somnolence—Cyclosporine—psoriasis	0.000177	0.000675	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000177	0.000675	CcSEcCtD
Montelukast—Oedema—Hydrocortisone—psoriasis	0.000177	0.000675	CcSEcCtD
Montelukast—Anaphylactic shock—Hydrocortisone—psoriasis	0.000177	0.000675	CcSEcCtD
Montelukast—Convulsion—Triamcinolone—psoriasis	0.000177	0.000674	CcSEcCtD
Montelukast—Asthenia—Mycophenolic acid—psoriasis	0.000177	0.000673	CcSEcCtD
Montelukast—Infection—Hydrocortisone—psoriasis	0.000176	0.00067	CcSEcCtD
Montelukast—Insomnia—Mycophenolate mofetil—psoriasis	0.000176	0.00067	CcSEcCtD
Montelukast—Dyspepsia—Cyclosporine—psoriasis	0.000175	0.000668	CcSEcCtD
Montelukast—Nausea—Hydroxyurea—psoriasis	0.000174	0.000665	CcSEcCtD
Montelukast—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000174	0.000665	CcSEcCtD
Montelukast—Pruritus—Mycophenolic acid—psoriasis	0.000174	0.000664	CcSEcCtD
Montelukast—Myalgia—Triamcinolone—psoriasis	0.000174	0.000663	CcSEcCtD
Montelukast—Nervous system disorder—Hydrocortisone—psoriasis	0.000173	0.000662	CcSEcCtD
Montelukast—Pneumonia—Methotrexate—psoriasis	0.000173	0.000662	CcSEcCtD
Montelukast—Somnolence—Mycophenolate mofetil—psoriasis	0.000173	0.000658	CcSEcCtD
Montelukast—Drowsiness—Methotrexate—psoriasis	0.000172	0.000658	CcSEcCtD
Montelukast—Infestation—Methotrexate—psoriasis	0.000172	0.000658	CcSEcCtD
Montelukast—Infestation NOS—Methotrexate—psoriasis	0.000172	0.000658	CcSEcCtD
Montelukast—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000172	0.000655	CcSEcCtD
Montelukast—Skin disorder—Hydrocortisone—psoriasis	0.000172	0.000655	CcSEcCtD
Montelukast—Fatigue—Cyclosporine—psoriasis	0.000172	0.000654	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000171	0.000652	CcSEcCtD
Montelukast—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000171	0.000652	CcSEcCtD
Montelukast—Pain—Cyclosporine—psoriasis	0.00017	0.000649	CcSEcCtD
Montelukast—Angioedema—Dexamethasone—psoriasis	0.000169	0.000645	CcSEcCtD
Montelukast—Angioedema—Betamethasone—psoriasis	0.000169	0.000645	CcSEcCtD
Montelukast—Diarrhoea—Mycophenolic acid—psoriasis	0.000168	0.000642	CcSEcCtD
Montelukast—Conjunctivitis—Methotrexate—psoriasis	0.000168	0.000639	CcSEcCtD
Montelukast—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000168	0.000639	CcSEcCtD
Montelukast—Immune system disorder—Prednisone—psoriasis	0.000167	0.000638	CcSEcCtD
Montelukast—Oedema—Triamcinolone—psoriasis	0.000167	0.000635	CcSEcCtD
Montelukast—Anaphylactic shock—Triamcinolone—psoriasis	0.000167	0.000635	CcSEcCtD
Montelukast—Pain—Mycophenolate mofetil—psoriasis	0.000166	0.000633	CcSEcCtD
Montelukast—Infection—Triamcinolone—psoriasis	0.000165	0.000631	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—IFNG—psoriasis	0.000164	0.00709	CbGpPWpGaD
Montelukast—Insomnia—Prednisolone—psoriasis	0.000164	0.000625	CcSEcCtD
Montelukast—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000163	0.00704	CbGpPWpGaD
Montelukast—Hepatobiliary disease—Methotrexate—psoriasis	0.000163	0.000622	CcSEcCtD
Montelukast—Gastrointestinal pain—Cyclosporine—psoriasis	0.000163	0.000621	CcSEcCtD
Montelukast—Dizziness—Mycophenolic acid—psoriasis	0.000163	0.00062	CcSEcCtD
Montelukast—Epistaxis—Methotrexate—psoriasis	0.000163	0.00062	CcSEcCtD
Montelukast—Paraesthesia—Prednisolone—psoriasis	0.000163	0.00062	CcSEcCtD
Montelukast—Mental disorder—Prednisone—psoriasis	0.000162	0.000619	CcSEcCtD
Montelukast—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000162	0.00697	CbGpPWpGaD
Montelukast—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000161	0.000615	CcSEcCtD
Montelukast—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000161	0.00695	CbGpPWpGaD
Montelukast—Convulsion—Dexamethasone—psoriasis	0.00016	0.000612	CcSEcCtD
Montelukast—Convulsion—Betamethasone—psoriasis	0.00016	0.000612	CcSEcCtD
Montelukast—Insomnia—Hydrocortisone—psoriasis	0.00016	0.00061	CcSEcCtD
Montelukast—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000159	0.00687	CbGpPWpGaD
Montelukast—Paraesthesia—Hydrocortisone—psoriasis	0.000159	0.000606	CcSEcCtD
Montelukast—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000159	0.000605	CcSEcCtD
Montelukast—Urticaria—Cyclosporine—psoriasis	0.000158	0.000603	CcSEcCtD
Montelukast—Myalgia—Dexamethasone—psoriasis	0.000158	0.000601	CcSEcCtD
Montelukast—Myalgia—Betamethasone—psoriasis	0.000158	0.000601	CcSEcCtD
Montelukast—Body temperature increased—Cyclosporine—psoriasis	0.000157	0.0006	CcSEcCtD
Montelukast—Abdominal pain—Cyclosporine—psoriasis	0.000157	0.0006	CcSEcCtD
Montelukast—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000157	0.00679	CbGpPWpGaD
Montelukast—Anxiety—Betamethasone—psoriasis	0.000157	0.000599	CcSEcCtD
Montelukast—Anxiety—Dexamethasone—psoriasis	0.000157	0.000599	CcSEcCtD
Montelukast—Vomiting—Mycophenolic acid—psoriasis	0.000156	0.000597	CcSEcCtD
Montelukast—Dyspepsia—Hydrocortisone—psoriasis	0.000156	0.000594	CcSEcCtD
Montelukast—Rash—Mycophenolic acid—psoriasis	0.000155	0.000592	CcSEcCtD
Montelukast—Dermatitis—Mycophenolic acid—psoriasis	0.000155	0.000591	CcSEcCtD
Montelukast—Pain—Prednisolone—psoriasis	0.000155	0.000591	CcSEcCtD
Montelukast—Hepatitis—Methotrexate—psoriasis	0.000155	0.00059	CcSEcCtD
Montelukast—Urticaria—Mycophenolate mofetil—psoriasis	0.000154	0.000588	CcSEcCtD
Montelukast—Headache—Mycophenolic acid—psoriasis	0.000154	0.000588	CcSEcCtD
Montelukast—Pharyngitis—Methotrexate—psoriasis	0.000154	0.000586	CcSEcCtD
Montelukast—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000153	0.000585	CcSEcCtD
Montelukast—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000153	0.000585	CcSEcCtD
Montelukast—Urinary tract disorder—Methotrexate—psoriasis	0.000153	0.000583	CcSEcCtD
Montelukast—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000153	0.000582	CcSEcCtD
Montelukast—Fatigue—Hydrocortisone—psoriasis	0.000153	0.000582	CcSEcCtD
Montelukast—Urethral disorder—Methotrexate—psoriasis	0.000152	0.000579	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000152	0.000579	CcSEcCtD
Montelukast—Pain—Hydrocortisone—psoriasis	0.000151	0.000577	CcSEcCtD
Montelukast—Oedema—Dexamethasone—psoriasis	0.000151	0.000576	CcSEcCtD
Montelukast—Oedema—Betamethasone—psoriasis	0.000151	0.000576	CcSEcCtD
Montelukast—Anaphylactic shock—Dexamethasone—psoriasis	0.000151	0.000576	CcSEcCtD
Montelukast—Anaphylactic shock—Betamethasone—psoriasis	0.000151	0.000576	CcSEcCtD
Montelukast—Insomnia—Triamcinolone—psoriasis	0.000151	0.000574	CcSEcCtD
Montelukast—Infection—Dexamethasone—psoriasis	0.00015	0.000573	CcSEcCtD
Montelukast—Infection—Betamethasone—psoriasis	0.00015	0.000573	CcSEcCtD
Montelukast—Paraesthesia—Triamcinolone—psoriasis	0.00015	0.00057	CcSEcCtD
Montelukast—Nervous system disorder—Dexamethasone—psoriasis	0.000148	0.000565	CcSEcCtD
Montelukast—Nervous system disorder—Betamethasone—psoriasis	0.000148	0.000565	CcSEcCtD
Montelukast—Agitation—Prednisone—psoriasis	0.000148	0.000565	CcSEcCtD
Montelukast—Thrombocytopenia—Dexamethasone—psoriasis	0.000148	0.000564	CcSEcCtD
Montelukast—Thrombocytopenia—Betamethasone—psoriasis	0.000148	0.000564	CcSEcCtD
Montelukast—Angioedema—Prednisone—psoriasis	0.000147	0.000562	CcSEcCtD
Montelukast—Hypersensitivity—Cyclosporine—psoriasis	0.000147	0.000559	CcSEcCtD
Montelukast—Dyspepsia—Triamcinolone—psoriasis	0.000147	0.000559	CcSEcCtD
Montelukast—Erythema multiforme—Methotrexate—psoriasis	0.000146	0.000558	CcSEcCtD
Montelukast—Nausea—Mycophenolic acid—psoriasis	0.000146	0.000557	CcSEcCtD
Montelukast—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000145	0.000552	CcSEcCtD
Montelukast—Urticaria—Prednisolone—psoriasis	0.000144	0.000549	CcSEcCtD
Montelukast—Cardiac disorder—Methotrexate—psoriasis	0.000144	0.000548	CcSEcCtD
Montelukast—Fatigue—Triamcinolone—psoriasis	0.000144	0.000548	CcSEcCtD
Montelukast—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000143	0.000546	CcSEcCtD
Montelukast—Asthenia—Cyclosporine—psoriasis	0.000143	0.000545	CcSEcCtD
Montelukast—Pain—Triamcinolone—psoriasis	0.000142	0.000543	CcSEcCtD
Montelukast—Pruritus—Cyclosporine—psoriasis	0.000141	0.000537	CcSEcCtD
Montelukast—Urticaria—Hydrocortisone—psoriasis	0.000141	0.000536	CcSEcCtD
Montelukast—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00014	0.00605	CbGpPWpGaD
Montelukast—Immune system disorder—Methotrexate—psoriasis	0.00014	0.000533	CcSEcCtD
Montelukast—Body temperature increased—Hydrocortisone—psoriasis	0.00014	0.000533	CcSEcCtD
Montelukast—Abdominal pain—Hydrocortisone—psoriasis	0.00014	0.000533	CcSEcCtD
Montelukast—Convulsion—Prednisone—psoriasis	0.00014	0.000533	CcSEcCtD
Montelukast—Mediastinal disorder—Methotrexate—psoriasis	0.00014	0.000532	CcSEcCtD
Montelukast—Asthenia—Mycophenolate mofetil—psoriasis	0.000139	0.000531	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000138	0.000525	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000138	0.000525	CcSEcCtD
Montelukast—Pruritus—Mycophenolate mofetil—psoriasis	0.000137	0.000524	CcSEcCtD
Montelukast—Arthralgia—Prednisone—psoriasis	0.000137	0.000524	CcSEcCtD
Montelukast—Myalgia—Prednisone—psoriasis	0.000137	0.000524	CcSEcCtD
Montelukast—Anxiety—Prednisone—psoriasis	0.000137	0.000522	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—NFKB1—psoriasis	0.000137	0.0059	CbGpPWpGaD
Montelukast—Insomnia—Betamethasone—psoriasis	0.000137	0.000521	CcSEcCtD
Montelukast—Insomnia—Dexamethasone—psoriasis	0.000137	0.000521	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000136	0.00052	CcSEcCtD
Montelukast—Diarrhoea—Cyclosporine—psoriasis	0.000136	0.000519	CcSEcCtD
Montelukast—Paraesthesia—Betamethasone—psoriasis	0.000136	0.000518	CcSEcCtD
Montelukast—Paraesthesia—Dexamethasone—psoriasis	0.000136	0.000518	CcSEcCtD
Montelukast—Mental disorder—Methotrexate—psoriasis	0.000136	0.000517	CcSEcCtD
Montelukast—Hypersensitivity—Prednisolone—psoriasis	0.000133	0.000509	CcSEcCtD
Montelukast—Dyspepsia—Betamethasone—psoriasis	0.000133	0.000507	CcSEcCtD
Montelukast—Dyspepsia—Dexamethasone—psoriasis	0.000133	0.000507	CcSEcCtD
Montelukast—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000133	0.000507	CcSEcCtD
Montelukast—Urticaria—Triamcinolone—psoriasis	0.000132	0.000505	CcSEcCtD
Montelukast—Body temperature increased—Triamcinolone—psoriasis	0.000132	0.000502	CcSEcCtD
Montelukast—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000132	0.00568	CbGpPWpGaD
Montelukast—Dizziness—Cyclosporine—psoriasis	0.000132	0.000502	CcSEcCtD
Montelukast—Oedema—Prednisone—psoriasis	0.000132	0.000502	CcSEcCtD
Montelukast—Anaphylactic shock—Prednisone—psoriasis	0.000132	0.000502	CcSEcCtD
Montelukast—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000131	0.00567	CbGpPWpGaD
Montelukast—Infection—Prednisone—psoriasis	0.000131	0.000499	CcSEcCtD
Montelukast—Gastrointestinal disorder—Dexamethasone—psoriasis	0.00013	0.000498	CcSEcCtD
Montelukast—Gastrointestinal disorder—Betamethasone—psoriasis	0.00013	0.000498	CcSEcCtD
Montelukast—Hypersensitivity—Hydrocortisone—psoriasis	0.00013	0.000497	CcSEcCtD
Montelukast—Fatigue—Betamethasone—psoriasis	0.00013	0.000497	CcSEcCtD
Montelukast—Fatigue—Dexamethasone—psoriasis	0.00013	0.000497	CcSEcCtD
Montelukast—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.00013	0.00559	CbGpPWpGaD
Montelukast—Pain—Dexamethasone—psoriasis	0.000129	0.000493	CcSEcCtD
Montelukast—Pain—Betamethasone—psoriasis	0.000129	0.000493	CcSEcCtD
Montelukast—Nervous system disorder—Prednisone—psoriasis	0.000129	0.000492	CcSEcCtD
Montelukast—Dizziness—Mycophenolate mofetil—psoriasis	0.000128	0.00049	CcSEcCtD
Montelukast—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	0.000128	0.00554	CbGpPWpGaD
Montelukast—Skin disorder—Prednisone—psoriasis	0.000128	0.000488	CcSEcCtD
Montelukast—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	0.000127	0.00548	CbGpPWpGaD
Montelukast—Asthenia—Hydrocortisone—psoriasis	0.000127	0.000484	CcSEcCtD
Montelukast—Vomiting—Cyclosporine—psoriasis	0.000127	0.000483	CcSEcCtD
Montelukast—Rash—Cyclosporine—psoriasis	0.000125	0.000479	CcSEcCtD
Montelukast—Dermatitis—Cyclosporine—psoriasis	0.000125	0.000478	CcSEcCtD
Montelukast—Pruritus—Hydrocortisone—psoriasis	0.000125	0.000477	CcSEcCtD
Montelukast—Headache—Cyclosporine—psoriasis	0.000125	0.000476	CcSEcCtD
Montelukast—Gastrointestinal pain—Betamethasone—psoriasis	0.000124	0.000471	CcSEcCtD
Montelukast—Gastrointestinal pain—Dexamethasone—psoriasis	0.000124	0.000471	CcSEcCtD
Montelukast—Vomiting—Mycophenolate mofetil—psoriasis	0.000123	0.000471	CcSEcCtD
Montelukast—Hypersensitivity—Triamcinolone—psoriasis	0.000123	0.000468	CcSEcCtD
Montelukast—Rash—Mycophenolate mofetil—psoriasis	0.000122	0.000467	CcSEcCtD
Montelukast—Dermatitis—Mycophenolate mofetil—psoriasis	0.000122	0.000466	CcSEcCtD
Montelukast—Headache—Mycophenolate mofetil—psoriasis	0.000122	0.000464	CcSEcCtD
Montelukast—Diarrhoea—Hydrocortisone—psoriasis	0.000121	0.000462	CcSEcCtD
Montelukast—Urticaria—Dexamethasone—psoriasis	0.00012	0.000458	CcSEcCtD
Montelukast—Urticaria—Betamethasone—psoriasis	0.00012	0.000458	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Prednisone—psoriasis	0.00012	0.000457	CcSEcCtD
Montelukast—Dizziness—Prednisolone—psoriasis	0.00012	0.000457	CcSEcCtD
Montelukast—Asthenia—Triamcinolone—psoriasis	0.000119	0.000456	CcSEcCtD
Montelukast—Body temperature increased—Betamethasone—psoriasis	0.000119	0.000456	CcSEcCtD
Montelukast—Abdominal pain—Betamethasone—psoriasis	0.000119	0.000456	CcSEcCtD
Montelukast—Abdominal pain—Dexamethasone—psoriasis	0.000119	0.000456	CcSEcCtD
Montelukast—Body temperature increased—Dexamethasone—psoriasis	0.000119	0.000456	CcSEcCtD
Montelukast—Insomnia—Prednisone—psoriasis	0.000119	0.000454	CcSEcCtD
Montelukast—Nausea—Cyclosporine—psoriasis	0.000118	0.000451	CcSEcCtD
Montelukast—Paraesthesia—Prednisone—psoriasis	0.000118	0.000451	CcSEcCtD
Montelukast—Pruritus—Triamcinolone—psoriasis	0.000118	0.000449	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—HCAR2—psoriasis	0.000118	0.00508	CbGpPWpGaD
Montelukast—Cough—Methotrexate—psoriasis	0.000118	0.000448	CcSEcCtD
Montelukast—Dizziness—Hydrocortisone—psoriasis	0.000117	0.000446	CcSEcCtD
Montelukast—Convulsion—Methotrexate—psoriasis	0.000117	0.000445	CcSEcCtD
Montelukast—ALOX5—Metabolism—NDUFA5—psoriasis	0.000116	0.005	CbGpPWpGaD
Montelukast—Dyspepsia—Prednisone—psoriasis	0.000116	0.000442	CcSEcCtD
Montelukast—Nausea—Mycophenolate mofetil—psoriasis	0.000115	0.00044	CcSEcCtD
Montelukast—Myalgia—Methotrexate—psoriasis	0.000115	0.000438	CcSEcCtD
Montelukast—Arthralgia—Methotrexate—psoriasis	0.000115	0.000438	CcSEcCtD
Montelukast—Rash—Prednisolone—psoriasis	0.000114	0.000436	CcSEcCtD
Montelukast—Dermatitis—Prednisolone—psoriasis	0.000114	0.000435	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000114	0.000435	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—CCL20—psoriasis	0.000114	0.00492	CbGpPWpGaD
Montelukast—Fatigue—Prednisone—psoriasis	0.000113	0.000433	CcSEcCtD
Montelukast—Headache—Prednisolone—psoriasis	0.000113	0.000433	CcSEcCtD
Montelukast—Vomiting—Hydrocortisone—psoriasis	0.000112	0.000429	CcSEcCtD
Montelukast—Rash—Hydrocortisone—psoriasis	0.000112	0.000425	CcSEcCtD
Montelukast—Dermatitis—Hydrocortisone—psoriasis	0.000111	0.000425	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.000111	0.00478	CbGpPWpGaD
Montelukast—Headache—Hydrocortisone—psoriasis	0.000111	0.000423	CcSEcCtD
Montelukast—Dizziness—Triamcinolone—psoriasis	0.00011	0.00042	CcSEcCtD
Montelukast—Anaphylactic shock—Methotrexate—psoriasis	0.00011	0.000419	CcSEcCtD
Montelukast—Infection—Methotrexate—psoriasis	0.000109	0.000417	CcSEcCtD
Montelukast—Asthenia—Betamethasone—psoriasis	0.000108	0.000414	CcSEcCtD
Montelukast—Asthenia—Dexamethasone—psoriasis	0.000108	0.000414	CcSEcCtD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000108	0.00467	CbGpPWpGaD
Montelukast—Nervous system disorder—Methotrexate—psoriasis	0.000108	0.000411	CcSEcCtD
Montelukast—Thrombocytopenia—Methotrexate—psoriasis	0.000108	0.000411	CcSEcCtD
Montelukast—Gastrointestinal pain—Prednisone—psoriasis	0.000108	0.00041	CcSEcCtD
Montelukast—Nausea—Prednisolone—psoriasis	0.000108	0.00041	CcSEcCtD
Montelukast—Pruritus—Dexamethasone—psoriasis	0.000107	0.000408	CcSEcCtD
Montelukast—Pruritus—Betamethasone—psoriasis	0.000107	0.000408	CcSEcCtD
Montelukast—Skin disorder—Methotrexate—psoriasis	0.000107	0.000407	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—TNF—psoriasis	0.000106	0.00459	CbGpPWpGaD
Montelukast—Vomiting—Triamcinolone—psoriasis	0.000106	0.000404	CcSEcCtD
Montelukast—Nausea—Hydrocortisone—psoriasis	0.000105	0.000401	CcSEcCtD
Montelukast—Rash—Triamcinolone—psoriasis	0.000105	0.0004	CcSEcCtD
Montelukast—Dermatitis—Triamcinolone—psoriasis	0.000105	0.0004	CcSEcCtD
Montelukast—Urticaria—Prednisone—psoriasis	0.000105	0.000399	CcSEcCtD
Montelukast—Headache—Triamcinolone—psoriasis	0.000104	0.000398	CcSEcCtD
Montelukast—Abdominal pain—Prednisone—psoriasis	0.000104	0.000397	CcSEcCtD
Montelukast—Body temperature increased—Prednisone—psoriasis	0.000104	0.000397	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—CCL20—psoriasis	0.000103	0.00446	CbGpPWpGaD
Montelukast—Diarrhoea—Dexamethasone—psoriasis	0.000103	0.000394	CcSEcCtD
Montelukast—Diarrhoea—Betamethasone—psoriasis	0.000103	0.000394	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—TAGAP—psoriasis	0.000102	0.0044	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	0.000102	0.0044	CbGpPWpGaD
Montelukast—Musculoskeletal discomfort—Methotrexate—psoriasis	0.0001	0.000382	CcSEcCtD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—CP—psoriasis	0.0001	0.00432	CbGpPWpGaD
Montelukast—Dizziness—Betamethasone—psoriasis	9.99e-05	0.000381	CcSEcCtD
Montelukast—Dizziness—Dexamethasone—psoriasis	9.99e-05	0.000381	CcSEcCtD
Montelukast—Insomnia—Methotrexate—psoriasis	9.95e-05	0.000379	CcSEcCtD
Montelukast—Nausea—Triamcinolone—psoriasis	9.89e-05	0.000377	CcSEcCtD
Montelukast—Paraesthesia—Methotrexate—psoriasis	9.88e-05	0.000377	CcSEcCtD
Montelukast—ALOX5—Metabolism—CYP2S1—psoriasis	9.86e-05	0.00426	CbGpPWpGaD
Montelukast—Somnolence—Methotrexate—psoriasis	9.78e-05	0.000373	CcSEcCtD
Montelukast—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.77e-05	0.00422	CbGpPWpGaD
Montelukast—Hypersensitivity—Prednisone—psoriasis	9.7e-05	0.00037	CcSEcCtD
Montelukast—Dyspepsia—Methotrexate—psoriasis	9.68e-05	0.000369	CcSEcCtD
Montelukast—Vomiting—Betamethasone—psoriasis	9.61e-05	0.000366	CcSEcCtD
Montelukast—Vomiting—Dexamethasone—psoriasis	9.61e-05	0.000366	CcSEcCtD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—CARM1—psoriasis	9.55e-05	0.00412	CbGpPWpGaD
Montelukast—Rash—Betamethasone—psoriasis	9.53e-05	0.000363	CcSEcCtD
Montelukast—Rash—Dexamethasone—psoriasis	9.53e-05	0.000363	CcSEcCtD
Montelukast—Dermatitis—Betamethasone—psoriasis	9.52e-05	0.000363	CcSEcCtD
Montelukast—Dermatitis—Dexamethasone—psoriasis	9.52e-05	0.000363	CcSEcCtD
Montelukast—Gastrointestinal disorder—Methotrexate—psoriasis	9.5e-05	0.000362	CcSEcCtD
Montelukast—Fatigue—Methotrexate—psoriasis	9.48e-05	0.000362	CcSEcCtD
Montelukast—Headache—Dexamethasone—psoriasis	9.47e-05	0.000361	CcSEcCtD
Montelukast—Headache—Betamethasone—psoriasis	9.47e-05	0.000361	CcSEcCtD
Montelukast—Asthenia—Prednisone—psoriasis	9.44e-05	0.00036	CcSEcCtD
Montelukast—Pain—Methotrexate—psoriasis	9.41e-05	0.000359	CcSEcCtD
Montelukast—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	9.37e-05	0.00404	CbGpPWpGaD
Montelukast—Pruritus—Prednisone—psoriasis	9.31e-05	0.000355	CcSEcCtD
Montelukast—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.25e-05	0.00399	CbGpPWpGaD
Montelukast—Diarrhoea—Prednisone—psoriasis	9e-05	0.000343	CcSEcCtD
Montelukast—Gastrointestinal pain—Methotrexate—psoriasis	8.99e-05	0.000343	CcSEcCtD
Montelukast—Nausea—Dexamethasone—psoriasis	8.98e-05	0.000342	CcSEcCtD
Montelukast—Nausea—Betamethasone—psoriasis	8.98e-05	0.000342	CcSEcCtD
Montelukast—Urticaria—Methotrexate—psoriasis	8.74e-05	0.000333	CcSEcCtD
Montelukast—Dizziness—Prednisone—psoriasis	8.7e-05	0.000332	CcSEcCtD
Montelukast—Body temperature increased—Methotrexate—psoriasis	8.69e-05	0.000332	CcSEcCtD
Montelukast—Abdominal pain—Methotrexate—psoriasis	8.69e-05	0.000332	CcSEcCtD
Montelukast—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.67e-05	0.00374	CbGpPWpGaD
Montelukast—ALOX5—Selenium Micronutrient Network—IL6—psoriasis	8.59e-05	0.00371	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.55e-05	0.00369	CbGpPWpGaD
Montelukast—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	8.43e-05	0.00364	CbGpPWpGaD
Montelukast—Vomiting—Prednisone—psoriasis	8.37e-05	0.000319	CcSEcCtD
Montelukast—Rash—Prednisone—psoriasis	8.3e-05	0.000316	CcSEcCtD
Montelukast—Dermatitis—Prednisone—psoriasis	8.29e-05	0.000316	CcSEcCtD
Montelukast—Headache—Prednisone—psoriasis	8.24e-05	0.000314	CcSEcCtD
Montelukast—Hypersensitivity—Methotrexate—psoriasis	8.1e-05	0.000309	CcSEcCtD
Montelukast—Asthenia—Methotrexate—psoriasis	7.89e-05	0.000301	CcSEcCtD
Montelukast—Nausea—Prednisone—psoriasis	7.82e-05	0.000298	CcSEcCtD
Montelukast—Pruritus—Methotrexate—psoriasis	7.78e-05	0.000297	CcSEcCtD
Montelukast—Diarrhoea—Methotrexate—psoriasis	7.53e-05	0.000287	CcSEcCtD
Montelukast—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.48e-05	0.00323	CbGpPWpGaD
Montelukast—Dizziness—Methotrexate—psoriasis	7.27e-05	0.000277	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	7.15e-05	0.00308	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	7.13e-05	0.00308	CbGpPWpGaD
Montelukast—Vomiting—Methotrexate—psoriasis	6.99e-05	0.000267	CcSEcCtD
Montelukast—Rash—Methotrexate—psoriasis	6.94e-05	0.000264	CcSEcCtD
Montelukast—Dermatitis—Methotrexate—psoriasis	6.93e-05	0.000264	CcSEcCtD
Montelukast—Headache—Methotrexate—psoriasis	6.89e-05	0.000263	CcSEcCtD
Montelukast—Nausea—Methotrexate—psoriasis	6.53e-05	0.000249	CcSEcCtD
Montelukast—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.45e-05	0.00278	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCL20—psoriasis	6.11e-05	0.00264	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	5.93e-05	0.00256	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—CXCL8—psoriasis	5.44e-05	0.00235	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	5.42e-05	0.00234	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.17e-05	0.00223	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—NDUFA5—psoriasis	5.03e-05	0.00217	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CARM1—psoriasis	4.82e-05	0.00208	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—NDUFA5—psoriasis	4.76e-05	0.00205	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.69e-05	0.00202	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	4.61e-05	0.00199	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.5e-05	0.00194	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP2S1—psoriasis	4.28e-05	0.00185	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CYP2S1—psoriasis	4.04e-05	0.00174	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	3.72e-05	0.00161	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SOCS1—psoriasis	3.36e-05	0.00145	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—NDUFA5—psoriasis	3.25e-05	0.0014	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—TYK2—psoriasis	3.21e-05	0.00138	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CXCL8—psoriasis	3.08e-05	0.00133	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.03e-05	0.00131	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CAT—psoriasis	2.96e-05	0.00128	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CXCL8—psoriasis	2.79e-05	0.00121	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP2S1—psoriasis	2.76e-05	0.00119	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—NDUFA5—psoriasis	2.64e-05	0.00114	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—LEP—psoriasis	2.48e-05	0.00107	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—APOE—psoriasis	2.48e-05	0.00107	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.46e-05	0.00106	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—NFKBIA—psoriasis	2.31e-05	0.000998	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—APOE—psoriasis	2.3e-05	0.000993	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP2S1—psoriasis	2.25e-05	0.00097	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.24e-05	0.000967	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CARM1—psoriasis	2.09e-05	0.000901	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PPARG—psoriasis	2e-05	0.000865	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CARM1—psoriasis	1.97e-05	0.000852	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.95e-05	0.000842	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TYK2—psoriasis	1.9e-05	0.000818	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—NDUFA5—psoriasis	1.74e-05	0.000752	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CXCL8—psoriasis	1.65e-05	0.000712	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—IL6—psoriasis	1.57e-05	0.000677	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—JUN—psoriasis	1.53e-05	0.000662	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CYP2S1—psoriasis	1.48e-05	0.00064	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—NFKB1—psoriasis	1.48e-05	0.000637	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.45e-05	0.000625	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CARM1—psoriasis	1.35e-05	0.000582	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—VEGFA—psoriasis	1.34e-05	0.000578	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—STAT3—psoriasis	1.33e-05	0.000573	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CAT—psoriasis	1.28e-05	0.000554	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.26e-05	0.000544	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CAT—psoriasis	1.21e-05	0.000524	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.18e-05	0.000508	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CARM1—psoriasis	1.1e-05	0.000474	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.03e-05	0.000443	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TP53—psoriasis	1.01e-05	0.000437	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—APOE—psoriasis	9.98e-06	0.000431	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—APOE—psoriasis	9.44e-06	0.000407	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IL6—psoriasis	9.27e-06	0.0004	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PPARG—psoriasis	8.69e-06	0.000375	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CAT—psoriasis	8.3e-06	0.000358	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PPARG—psoriasis	8.22e-06	0.000355	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CARM1—psoriasis	7.24e-06	0.000312	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CAT—psoriasis	6.75e-06	0.000291	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—APOE—psoriasis	6.45e-06	0.000278	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PPARG—psoriasis	5.61e-06	0.000242	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—APOE—psoriasis	5.25e-06	0.000226	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PPARG—psoriasis	4.57e-06	0.000197	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CAT—psoriasis	4.45e-06	0.000192	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—APOE—psoriasis	3.46e-06	0.000149	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PPARG—psoriasis	3.01e-06	0.00013	CbGpPWpGaD
